Craig-Hallum lowers PT on Xtant Medical (XTNT) on expected EBITDA margin compression
Tweet Send to a Friend
Craig-Hallum analyst Chase Knickerbocker reiterated a Buy rating and lowered the price target to $1.20 (from $1.50) on Xtant Medical ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
